Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document ianalumab - BAFF-R inhibitor Company overview Financial review Conclusions NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) Systemic lupus erythematosus Indication Phase Phase 3 Patients 406 Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Cardiovascular, Renal and Metabolic > Immunology Neuroscience Oncology Other Global Health Abbreviations Primary Outcome Measures Arms Intervention Proportion of participants on monthly ianalumab achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4) [ Time Frame: Week 60 ] Experimental: lanalumab s.c. monthly Target Patients Readout Milestone(s) Experimental: lanalumab s.c. quarterly Placebo Comparator: Placebo s.c. monthly Patients with active systemic lupus erythematosus (SLE) 2027 Publication TBD References ianalumab - BAFF-R inhibitor NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) Systemic lupus erythematosus Phase 3 Indication Phase Patients 280 Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) Proportion of participants achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4) [ Time Frame: Week 60 ] Experimental: ianalumab s.c. monthly Placebo Comparator: placebo s.c. monthly Patients with active systemic lupus erythematosus (SLE) 2027 Publication TBD □ NOVARTIS Reimagining Medicine | Novartis Q4 Results | January 31, 2024 61

View entire presentation